The BalancedInvestor Club

BNR Market Analysis

Overview

Fundamentals

P/E ratio—
EPS (TTM)$-0.760.0% YoY
Profit margin-10.3%HEALTHCARE
Market cap$180.3MMicro cap

Valuation

Forward P/E
—
PEG ratio
—
P/B
2.30
P/S (TTM)
0.33
EV/EBITDA
-0.17

Profitability & growth

ROE (TTM)
-9.9%
Operating margin
-9.5%
Revenue growth YoY
0.2%
Dividend yield
—
Beta
1.60
Last earnings
Mar 31, 2026 · Reported $-0.21
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Burning Rock Biotech Ltd

Burning Rock Biotech Limited primarily develops and provides screening tests for cancer therapies in the People's Republic of China. The company is headquartered in Guangzhou, China.

Classification

Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NASDAQ
Country
China
Currency
USD

Company profile

HQ
NO. 5, XINGDAO RING ROAD NORTH, GUANGZHOU
Fiscal year end
December
Latest quarter
Mar 31, 2026
Market cap$180.3M
Shares outstanding$8.8M
52W high$41.72
52W low$2.26

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer